Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve

Oriol, B.; Barrio, A.; Pacheco, A.; Serna, J.; Zuzuarregui, J.L.; Garcia-Velasco, Juan A.

doi:10.1016/j.fertnstert.2007.08.032

Cited by 58 publications

(45 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the systematic review of all studies evaluating the effects of MTX on subsequent ovarian reserve, only one of seven studies was prospectively analyzed [19]. It is possible that a significant number of women who receive MTX do not seek or complete an additional ART cycle and are therefore not included in these retrospective analyses.…”

Section: Discussionmentioning

confidence: 99%

“…One additional study was excluded because none of the patients were undergoing ART [15]. Seven studies met all the inclusion criteria [16][17][18][19][20][21][22]. As shown in Table 1, five of the studies were retrospective cohort analyses and two were prospective observational studies [19,20].…”

Section: Systematic Reviewmentioning

confidence: 99%

“…Seven studies met all the inclusion criteria [16][17][18][19][20][21][22]. As shown in Table 1, five of the studies were retrospective cohort analyses and two were prospective observational studies [19,20]. All of the studies used a paired analysis of IVF cycles before and after MTX, but two studies also compared to a control group of patients who underwent salpingectomy [17,22].…”

Section: Systematic Reviewmentioning

confidence: 99%

See 2 more Smart Citations

Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes

Boots¹,

Hill²,

Feinberg

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The purpose of this research was to study whether methotrexate (MTX) as treatment for ectopic pregnancy (EP) impacts the future fertility of women undergoing assisted reproductive technology (ART) Methods In a systematic review and multi-center retrospective cohort from four academic and private fertility centers, 214 women underwent an ART cycle before and after receiving MTX as treatment for an EP. Measures of ovarian reserve and responsiveness and rates of clinical pregnancy (CP) and live birth (LB) were compared in the ART cycles prior and subsequent to MTX. Results Seven studies were identified in the systematic review, and primary data from four institutions was included in the final analysis. Women were significantly older in post-MTX cycles (35.3 vs 34.7 years). There were no differences in follicle stimulating hormone, antral follicle count, duration of stimulation, oocytes retrieved, or fertilization rate between pre-and post-MTX cycles. However, post-MTX cycles received a significantly higher total dose of gonadotropins (4206 vs 3961 IU). Overall, 42 % of women achieved a CP and 35 % achieved a LB in the post-MTX ART cycle, which is similar to national statistics. Although no factors were identified that were predictive of LB in young women, the number of oocytes retrieved in the previous ART cycle and current AFC were predictive of LB (AUC 0.76, 0.75) for the older women. Conclusions MTX does not influence ovarian reserve, response to gonadotropin stimulation, and CP or LB rate after ART. MTX remains a safe and effective treatment option for women with asymptomatic EPs.Capsule As treatment for an ectopic pregnancy, methotrexate does not affect ovarian reserve, response to gonadotropin stimulation, clinical pregnancy, or live birth rates in subsequent assisted reproductive tenchology cycles.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Systematic Reviewmentioning

confidence: 99%

Section: Systematic Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes

Boots¹,

Hill²,

Feinberg

et al. 2016

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…MTX is widely used for the treatment of ectopic pregnancies (EP) which counts approximately for 1-2% of all pregnancies with high risk for maternal mortality and morbidity and affects rapidly proliferating cells such as trophoblastic tissue of EP [2]. Single or multiple dose MTX administration are methods currently performed for the medical treatment of EP.…”

Section: Introductionmentioning

confidence: 99%

“…Salpingectomy is a surgical option for the treatment of selected patients with EP [3]. Both surgical and medical methods for EP were found to affect ovarian reserve by impairing the proliferation of the germinal cells or blood supply of the ovary [2,4]. However, recently published studies suggested that single-dose MTX in the treatment of EP is safer and may be the first treatment choice [5,6].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the effects of single or multiple dose methotrexate administration, salpingectomy on ovarian reserve of rat with the measurement of anti-Müllerian hormone (AMH) levels and histological analysis

Ulug

Öner

2014

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Ultrasound monitoring in patients undergoing in‐vitro fertilization after methotrexate treatment for ectopic pregnancy

Provansal

Agostini

Lacroix

et al. 2009

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve

Cited by 58 publications

References 26 publications

Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes

Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes

Evaluation of the effects of single or multiple dose methotrexate administration, salpingectomy on ovarian reserve of rat with the measurement of anti-Müllerian hormone (AMH) levels and histological analysis

Ultrasound monitoring in patients undergoing in‐vitro fertilization after methotrexate treatment for ectopic pregnancy

Contact Info

Product

Resources

About